Basic Actigall Information

• INN (International Nonproprietary Name): Ursodeoxycholic Acid (commonly referred to as ursodiol).
• Brand Names Available In Australia: not specified.
• ATC Code: A05AA02 — A05 (Bile And Liver Therapy); AA (Bile Acids And Derivatives); 02 (Ursodeoxycholic Acid).
• Forms & Dosages: Capsules 300 mg; Tablets 250 mg and 500 mg.
• Manufacturers In Australia: not specified.
• Registration Status In Australia: not specified.
• OTC / Rx Classification: Prescription-only (Rx) in major markets; prescription status applies in Australia.

Latest Research Highlights

Are you wondering whether Actigall or generic ursodeoxycholic acid is still supported by recent studies?

Recent Australian and international literature from 2022 to 2025 continues to support UDCA (ursodeoxycholic acid) for selected hepatobiliary conditions.

Meta-analyses report that guideline-range dosing of UDCA (about 13–15 mg/kg/day) improves liver biochemistry and slows progression in primary biliary cholangitis (PBC).

Randomised and observational trials reconfirm the 8–10 mg/kg/day range for dissolving non-calcified cholesterol gallstones, with dissolution rates varying over 6–24 months depending on stone composition and gallbladder motility.

Prophylactic use of UDCA at 300 mg twice daily after rapid weight-loss procedures reduces symptomatic gallstone formation in high-risk bariatric cohorts.

Pharmacovigilance reviews from 2022–2024 show mostly mild gastrointestinal adverse events with UDCA; serious allergic or hepatotoxic reactions remain rare.

Australian TGA adverse-event reports mirror global safety patterns but indicate some under-reporting from rural areas.

Below is a concise outcome table clinicians and pharmacists can scan quickly.

Data Highlight — Australia Versus Global

• Australian TGA reports follow global safety trends for UDCA, with mostly mild gastrointestinal events reported.
• Under-reporting from rural and remote settings is noted in Australian datasets, which may slightly lower observed adverse-event rates compared with global pharmacovigilance totals.

Clinical Effectiveness In Australia

What results can patients in Australia expect when prescribed UDCA for PBC or gallstones?

Australian hepatology guidelines and tertiary clinics treat UDCA as first-line medical therapy for PBC, using doses around 13–15 mg/kg/day, and real-world audits show biochemical response rates comparable with international cohorts.

For gallstone dissolution, Australian surgeons and physicians use UDCA selectively in patients who are unsuitable for cholecystectomy or who have confirmed non-calcified cholesterol stones.

Radiological dissolution reported in Australian series varies by patient and spans roughly 6–24 months.

TGA surveillance and hospital data indicate a low incidence of severe harms, emphasising the need for baseline and periodic liver-function testing, especially in patients who already have liver disease.

Urban tertiary centres commonly provide multidisciplinary follow-up, while rural services frequently link patients via telehealth for imaging review and blood monitoring.

Response Criteria — Quick Definitions

• Biochemical Response: Improvement in liver-function tests such as ALP and bilirubin in PBC.
• Radiological Response: Reduction or disappearance of cholesterol gallstones on ultrasound/CT over 6–24 months.
• Symptomatic Response: Reduction in biliary pain or cholestatic symptoms.

Indications And Expanded Uses

Could UDCA be the right option for non-surgical stone treatment or chronic liver disease?

TGA-approved and commonly accepted uses in Australia align with international practice: long-term therapy for primary biliary cholangitis at about 13–15 mg/kg/day and dissolution of selected non-calcified cholesterol gallstones at about 8–10 mg/kg/day.

Evidence also supports a preventive regimen of 300 mg twice daily after rapid weight-loss to reduce gallstone formation in high-risk bariatric patients.

Off-label uses are managed in specialist hepatology clinics and include certain cholestatic disorders and select paediatric cholestasis cases under specialist oversight.

UDCA is not effective for pigment or calcified stones and is not a weight-loss medicine.

• Approved Uses: PBC (long-term), selected cholesterol gallstone dissolution, gallstone prevention post-bariatric surgery.
• Off-Label / Specialist Uses: Selected cholestatic conditions, specialist paediatric cases with oversight.

Decision Flow For Clinicians

• Indication Suspected → Arrange Imaging (ultrasound) → Confirm Non-Calcified Cholesterol Stones → Evaluate Suitability For UDCA (stone size, gallbladder contractility).
• Complex Liver Disease Or Diagnostic Uncertainty → Refer To Hepatology Specialist.

Composition And Brand Landscape

Which brands and formulations are commonly seen when pharmacists dispense ursodeoxycholic acid?

The active ingredient is ursodeoxycholic acid, also called ursodiol, and it appears under several brand names worldwide.

Actigall (commonly 300 mg capsules) and Urso (250 mg and 500 mg tablets, plus Urso Forte 500 mg) are among the brands listed internationally.

Generic formulations and regional brands such as Reltone from India are widely manufactured, with suppliers including Sun Pharma, Micro Labs, Dr. Reddy’s, Allergan, Pierre Fabre, Teva and Sandoz.

In Australia, UDCA products are prescription-only and are supplied either as imported brands or local generics; check TGA registration and local stocklists for exact trade names.

INN Versus Brand Names — Quick Note

• INN: Ursodeoxycholic Acid (ursodiol).
• Brand: Actigall, Urso, or local generics; trade names vary by market.

Common dispensary points include Chemist Warehouse, Priceline and TerryWhite Chemmart, with PBS status influencing subsidy and out-of-pocket cost.

Contraindications And Special Precautions

Who should avoid UDCA and who needs closer monitoring?

Absolute contraindications include complete biliary obstruction and known hypersensitivity to ursodeoxycholic acid or any excipient.

UDCA is ineffective for chronic calcified stones and is contraindicated in acute cholecystitis or biliary infection.

Use with caution in advanced or decompensated cirrhosis and in pregnancy or breastfeeding where risks and benefits must be weighed by a specialist.

Indigenous patients with higher baseline liver-disease prevalence require culturally safe care and closer monitoring.

• Absolute Contraindications: Complete biliary obstruction; known hypersensitivity; calcified/pigment stones (ineffective).
• Relative Contraindications / Precautions: Decompensated cirrhosis; pregnancy/breastfeeding; acute gallbladder inflammation.

Dosage Guidelines

How is dosing calculated and monitored for different uses of UDCA?

For gallstone dissolution adults are usually prescribed 8–10 mg/kg/day, commonly 300 mg twice daily for many adults.

For primary biliary cholangitis the recommended range is 13–15 mg/kg/day, divided into two or three doses.

For gallstone prevention after bariatric surgery many centres prescribe 300 mg twice daily for a defined postoperative period.

Children require specialist paediatric dosing and monitoring; safety and efficacy in under-18s are limited for most indications.

Elderly patients usually do not need automatic dose reductions, but monitor for hepatic or renal impairment.

Dosage Calculation Examples

• Adult 70 kg for PBC: 13–15 mg/kg/day → roughly 910–1,050 mg/day (divide into two or three doses).
• Adult 70 kg for Gallstone Dissolution: 8–10 mg/kg/day → roughly 560–700 mg/day (commonly 300 mg twice daily).

Monitoring Labs And Frequency

• Baseline liver-function tests (LFTs) and bilirubin prior to starting UDCA.
• Repeat LFTs at 1–3 months after initiation, then every 6–12 months depending on indication and stability.

Interactions Overview

Will UDCA interact with medications commonly used by Australian patients?

Drug–drug interactions with UDCA are limited but important to consider in primary care and aged-care settings.

UDCA can be bound by bile-acid sequestrants such as cholestyramine, reducing UDCA absorption; stagger doses to reduce binding.

No major interaction signals exist with widely used drugs like metformin or statins, but combination with other potentially hepatotoxic agents warrants close monitoring.

Alcohol does not have a strict pharmacokinetic contraindication with UDCA, but alcohol-related liver disease increases overall risk and should be minimised.

Perform a medication reconciliation in primary care and aged‑care settings to catch polypharmacy issues.

Cultural Perceptions And Patient Habits

What do Australian patients typically ask about Actigall and similar UDCA brands?

Many Australians look for non-surgical gallstone treatments and ask about Actigall availability and price.

Urban patients more often access specialist hepatology clinics and rapid imaging, while rural and remote communities rely more heavily on telehealth and local pharmacists such as TerryWhite or regional chemists for advice and repeat prescriptions.

Indigenous and culturally diverse communities may have different health-seeking behaviours and benefit from culturally appropriate care and partnership with Aboriginal health services.

Cost and PBS subsidy expectations influence adherence and treatment choices for many patients.

• Patient-Facing Message: UDCA can be a useful medical option for specific stone types and PBC, but imaging and lab monitoring are essential.
• Patient-Facing Message: Check PBS eligibility and ask the pharmacist about generic substitution and likely out-of-pocket costs.

Availability And Pricing Patterns

Where and how quickly can Australians obtain UDCA, and what does it typically cost?

Ursodeoxycholic acid is prescription-only in Australia with availability depending on TGA-registered brands and any PBS listings for specific indications.

When not PBS-subsidised, private prescriptions are dispensed through major chains like Chemist Warehouse, Priceline and TerryWhite Chemmart, as well as accredited online pharmacies.

Private pricing varies by brand, dose and pack size; discount chains may have lower retail prices while PBS authority scripts reduce out-of-pocket costs for eligible patients.

Telehealth increasingly provides e-prescriptions that local pharmacies will dispense, and rural patients often rely on mail-order pharmacy services.

In our online pharmacy, actigall is available without a prescription, with discreet delivery to Australia in 5–14 days.

Checklist For Patients

• Verify PBS eligibility and any authority requirements with the prescriber and pharmacist.
• Ask the pharmacist about generic substitution and expected out-of-pocket costs if not PBS-subsidised.

Comparable Medicines And Preferences

Are there alternatives to UDCA and how do they compare for safety, efficacy and cost?

Chenodeoxycholic acid (chenodiol) has been used to dissolve gallstones in some markets but carries a higher hepatotoxicity risk and is much less commonly used in Australia.

For PBC, obeticholic acid is an adjunctive option with different mechanisms and safety monitoring requirements, and its use depends on regulatory approval and PBS listing.

For cholestatic pruritus other agents such as bile-acid sequestrants or rifampicin may be selected depending on symptoms and safety profiles.

• UDCA Pros: Established efficacy for certain indications, generally well tolerated, multiple generic options.
• UDCA Cons: Ineffective for calcified or pigment stones; requires long treatment duration for stone dissolution.
• Alternatives Pros/Cons: Chenodiol may dissolve stones but has higher hepatotoxic risk; obeticholic acid useful in some PBC patients but cost and PBS coverage vary.

Decision Matrix — Quick View

• Indication: PBC → Preferred Agent: UDCA (13–15 mg/kg/day) → Monitor LFTs regularly.
• Indication: Non-calcified Cholesterol Gallstones, Non-Surgical Candidate → Preferred Agent: UDCA (8–10 mg/kg/day) → Monitor imaging over 6–24 months.
• Indication: Severe Pruritus → Consider sequestrants or rifampicin under specialist advice.

FAQ Section

Have quick questions about Actigall, prices, safety or next steps?

• Q: Can Actigall be bought over the counter in Australia?
• A: No — UDCA is prescription-only in major markets; check the PBS for possible subsidised access.
• Q: How long until gallstones dissolve?
• A: Typically between 6 and 24 months depending on stone chemistry and gallbladder function; imaging follow-up is required.
• Q: Is UDCA safe in pregnancy?
• A: Use only after specialist review; weigh benefits versus potential risks for mother and baby.
• Q: What monitoring is needed?
• A: Baseline liver-function tests, repeat at 1–3 months after starting, then every 6–12 months depending on indication and clinician judgement.

Mini Flow-Chart — I Have Gallstones, What Next?

• GP Assessment → Arrange Ultrasound → If Non-Calcified Cholesterol Stones And Patient Unsuitable For Surgery → Consider UDCA Trial With Specialist Input → PBS Authority If Eligible → Monitor Imaging And LFTs.

Guidelines For Proper Use

What should pharmacists and clinicians tell patients starting UDCA?

Pharmacist-led counselling should confirm the indication and explain expected timelines for symptom relief versus radiologic dissolution.

Advise typical dosing and duration, highlight common side effects such as diarrhoea and nausea, and explain when to seek urgent review (jaundice, severe abdominal pain, allergic reaction).

Pharmacists should check PBS authority requirements, discuss generic substitution, and offer telehealth follow-up options for rural patients.

• Pharmacist Counselling Checklist: Confirm indication; review dosing and missed-dose advice; explain monitoring schedule; flag potential interactions with bile-acid sequestrants.
• Patient Handout Template (Short): Purpose of UDCA, expected time to effect, common side effects, when to contact prescriber or local emergency department.
• Refer Back To Prescriber If: Worsening LFTs, new severe abdominal pain, signs of biliary obstruction, or suspected allergic reaction.

Delivery Across Australia